Taroh Satoh

22PUBLICATIONS
175CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|Mar 30, 2026
Prognostic Biomarkers and Immunotherapeutic Insights of Circulating Tumor DNA Analysis in Advanced Esophageal Squamous Cell Carcinoma From SCRUM-MONSTAR GOZILA Substudy.

Yuqing Duan, Tadayoshi Hashimoto, Taro Shibuki

|Sep 30, 2025
Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations.

James J Harding, Do-Youn Oh, Teresa Macarulla Mercade

|May 23, 2025
Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial.

Daisuke Sakai, Shigenori Kadowaki, Ryohei Kawabata

|May 09, 2025
Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study.

Kentaro Sawada, Riu Yamashita, Shunsuke A Sakai

|Apr 17, 2025
In Vivo Engineered CAR-T Cell Therapy: Lessons Built from COVID-19 mRNA Vaccines.

Sikun Meng, Tomoaki Hara, Yutaka Miura

|Apr 10, 2025
Benefits of Combining Circulating Tumor DNA With Tissue and Longitudinal Circulating Tumor DNA Genotyping in Advanced Solid Tumors: SCRUM-Japan MONSTAR-SCREEN-1 Study.

Takao Fujisawa, Yoshiaki Nakamura, Hideaki Bando

Pageof 4

Frequent Collaborators

10 joint publications

Takayuki Yoshino

9 joint publications

Yoshiaki Nakamura

9 joint publications

Hideaki Bando

8 joint publications

Yu Sunakawa